glp-1 novo Nordisk Finds Medicare Patients Prefer Pill Over Shot for Weight Loss Novo Nordisk launches Wegovy weight-loss

Excellent for long-term metabolic health

Torng, S, Veedfald, S, Rosenkilde, MM, Hartmann, B, Holst, JJ

The differentiator this review lands on is sequence: understanding your pathway biology before starting turns a prescription into an informed conversation with your provider

The same survey identified weight loss as the leading reason for considering a GLP-1 or alternative (Canada: 58 per cent

The physiological roles of secretin and its receptor

The Asia-Pacific region is the fastest-growing oral GLP-1 market due to the rapidly increasing prevalence of diabetes and obesity, particularly in China, India, and Japan